Merck Shares Hit After Guidance Falls Short, Gardasil Challenge
The drugmaker’s guidance was affected by a pause in shipments of its top-selling vaccine to China from February through at ...
Merck projects $64.1B-$65.6B revenue in 2025 amid WINREVAIR growth and GARDASIL rebasing
Q4 2024 Management View Rob Davis emphasized Merck's strong performance in 2024, driven by demand for KEYTRUDA, the launch of WINREVAIR, and robust growth in Animal Health. Davis highlighted ...
Merck reports Q4 adjusted EPS $1.72, consensus $1.67
Reports Q4 revenue $15.6B, consensus $15.51B. “We delivered strong growth in 2024, reflecting demand for our innovative portfolio, including ...
Merck’s (NYSE:MRK) Q4 Sales Top Estimates But Stock Drops
Global pharmaceutical company Merck (NYSE:MRK) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with ...
Merck stock slides as 2025 earnings outlook misses estimates
Merck (MRK) shares drop 8% premarket as 2025 outlook falls short of Wall Street estimates, despite beating Q4 expectations ...
Merck’s soft guidance overshadows quarterly beat to send stock down 8%
Merck’s stock tumbled 6% early Tuesday, after the drug company’s softer-than-expected guidance for the current year offset ...
Merck (MRK) Q4 2024 Earnings Call Transcript
Welcome to the Merck & Company Q4 sales and earnings conference call. [Operator instructions] This call is being recorded.
Hosted on MSN11h
What Are Wall Street Analysts’ Target Price for Merck Stock?
Rahway, New Jersey-based Merck & Co., Inc. (MRK) functions as a healthcare company. Valued at $252.4 billion by market cap, ...
dvm3605d
Animal health organizations launch business simulation challenges
VBMA students are invited to compete in a scholarship program aiming to prepare the next generation of veterinarians for entrepreneurship ...